A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer
S1007 Circulating Biomarker Assessment for Late Relapse Translational Medicine (CBALR TM Substudy (Step 3)) is Closed to Accrual, effective October 15, 2023.
S1007 is permanently closed to accrual for Step 1 registration effective October 1, 2015 at 11:59 p.m. PST. The study is permanently closed to accrual for Step 2 registration effective October 15, 2015 at 11:59 p.m. PST.
